Trial Profile

A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levodopa/carbidopa (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Sponsors IMPAX Laboratories

Most Recent Events

04 Dec 2018 Results assessing efficacy of single dose of IPX203 in advanced Parkinson's Disease, published in the Clinical Neuropharmacology.
08 Jun 2017 Primary endpoint (Off time per the Assessment of Subjects Motor State) has been met as per the results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com